

IN THE CLAIMS

1-20. (Cancelled)

21. (Withdrawn – Currently Amended) A method for the production of the a single-chain polypeptide according to Claim [[13]] 28, comprising culturing the host cell transformed with nucleic acids encoding the polypeptide, expressing the nucleic acid, collecting the expressed polypeptide, and purifying the polypeptide.

22. (Withdrawn – Currently Amended) A method for the production of a diabody-type bispecific antibody, comprising assembling the single-chain polypeptides produced by the method of Claim [[21]] 28 to form a diabody-type bispecific antibody, and separating and collecting the diabody-type antibody.

23. (Cancelled)

24. (Currently Amended) [[The]] A pharmaceutical preparation ~~according~~ comprising the diabody-type ~~specific~~ bispecific antibody according to claim 28.

25. (Previously Presented) The pharmaceutical preparation according to Claim 24 for use in increasing the production of cytokines by the cells having phagocytosis or cytotoxic activity.

26. (Cancelled)

27. (Withdrawn) A method for increasing the production of cytokines by the cells having phagocytosis or cytotoxic activity, comprising adding the diabody-type bispecific antibody according to Claim 28 to a culture system containing the cells having phagocytosis or cytotoxic activity and tumor cells expressing the human EGF receptors.

28. (Currently Amended) A humanized diabody-type bispecific antibody ~~consisting of two single-chain polypeptides~~ selected from the group of (A)-(D) consisting of:

(A) a first single-chain polypeptide comprising

a heavy chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:43, and a light chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:46, and

a second single-chain polypeptide comprising

a ~~heavy~~ light chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:44, and a ~~light~~ heavy chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:45,

(B) a first single-chain polypeptide comprising

a heavy chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:43 and a light chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:46, and

a second single-chain polypeptide comprising a ~~heavy~~ light chain comprising a variable

region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:44 and a ~~light~~ heavy chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:45,

wherein Met at position 48 and Ala at position 93 of the ~~light~~ heavy chain sequence according to SEQ ID NO:45 are replaced by Ile and Thr, respectively

(C) a first single-chain polypeptide comprising

a heavy chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:43 and a light chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:46, and

a second single-chain polypeptide comprising

a ~~heavy~~ light chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:44 and a ~~light~~ heavy chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:45,

wherein Arg at position 66, Met at position 69, Arg at position 71 and Thr at position 73 of the ~~light~~ heavy chain sequence according to SEQ ID NO:45 are replaced by Lys, Leu, Val and Arg, respectively, and

(D) a first single-chain polypeptide comprising

a heavy chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:43 and a light chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:46, and

a second single-chain polypeptide comprising

a ~~heavy~~ light chain comprising a variable region comprising ~~[[an]]~~ the amino acid

sequence according to SEQ ID NO:44 and a ~~light~~ heavy chain comprising a variable region comprising ~~[[an]]~~ the amino acid sequence according to SEQ ID NO:45,

wherein Met at position 48, Arg at position 66, Met at position 69, Arg at position 71, Thr at position 73 and Ala at position 93 of the ~~light~~ heavy chain sequence according to SEQ ID NO:45 are replaced by Ile, Lys, Leu, Val, Arg and Thr, respectively.

29. (Previously Presented) The humanized diabody-type bispecific antibody according to claim 28 which is (A).

30. (Previously Presented) The humanized diabody-type bispecific antibody according to claim 28 which is (B).

31. (Previously Presented) The humanized diabody-type bispecific antibody according to claim 28 which is (C).

32. (Previously Presented) The humanized diabody-type bispecific antibody according to claim 28 which is (D).